These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 30037377

  • 1. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
    Yin L, Lu Y.
    Zhongguo Fei Ai Za Zhi; 2018 Jul 20; 21(7):553-559. PubMed ID: 30037377
    [Abstract] [Full Text] [Related]

  • 2. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T, Liang Y, Zhu V, Ou SI.
    Lung Cancer; 2017 Jan 20; 103():27-37. PubMed ID: 28024693
    [Abstract] [Full Text] [Related]

  • 3. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM.
    J Thorac Oncol; 2017 Jan 20; 12(1):137-140. PubMed ID: 27666659
    [Abstract] [Full Text] [Related]

  • 4. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ.
    J Thorac Oncol; 2016 Aug 20; 11(8):1242-1245. PubMed ID: 27343442
    [Abstract] [Full Text] [Related]

  • 5. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
    Qin RY, Liu LS, Zhang HY, Lu CH, Guo XY, Zhang LY, Yuan XB, Xue HH.
    Medicine (Baltimore); 2021 Jan 29; 100(4):e24300. PubMed ID: 33530219
    [Abstract] [Full Text] [Related]

  • 6. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
    Huang C, Zou Q, Liu H, Qiu B, Li Q, Lin Y, Liang Y.
    Curr Treat Options Oncol; 2020 Apr 18; 21(4):33. PubMed ID: 32306194
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
    Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T.
    Lung Cancer; 2018 Sep 18; 123():76-82. PubMed ID: 30089599
    [Abstract] [Full Text] [Related]

  • 10. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
    Ding G, Wang J, Ding P, Wen Y, Yang L.
    Cancer Biol Ther; 2019 Sep 18; 20(6):837-842. PubMed ID: 30744539
    [Abstract] [Full Text] [Related]

  • 11. [Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 
Skipping Mutation].
    Editorial Office of Chinese Journal of Lung Cancer.
    Zhongguo Fei Ai Za Zhi; 2023 Jun 20; 26(6):416-428. PubMed ID: 37488079
    [Abstract] [Full Text] [Related]

  • 12. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
    Kauffmann-Guerrero D, Kahnert K, Kumbrink J, Syunyaeva Z, Tufman A, Huber RM.
    Clin Lung Cancer; 2019 Jan 20; 20(1):59-62. PubMed ID: 30341016
    [No Abstract] [Full Text] [Related]

  • 13. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA, Geurts-Giele WRR, von der TJH, Meijssen IC, Dinjens WNM, Aerts JGJV, Dingemans AMC, Lolkema MP, Paats MS, Dubbink HJ.
    Lung Cancer; 2020 Feb 20; 140():46-54. PubMed ID: 31862577
    [Abstract] [Full Text] [Related]

  • 14. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
    Shalata W, Yakobson A, Weissmann S, Oscar E, Iraqi M, Kian W, Peled N, Agbarya A.
    Oncology; 2022 Feb 20; 100(9):467-474. PubMed ID: 35679833
    [Abstract] [Full Text] [Related]

  • 15. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
    Jin W, Shan B, Liu H, Zhou S, Li W, Pan J, Lin L, Hu D, Pan Y.
    J Thorac Oncol; 2019 Jul 20; 14(7):e137-e139. PubMed ID: 31055074
    [No Abstract] [Full Text] [Related]

  • 16. [Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer].
    Han S, Ma X, Fang J.
    Zhongguo Fei Ai Za Zhi; 2020 Jul 20; 23(7):609-614. PubMed ID: 32702795
    [Abstract] [Full Text] [Related]

  • 17. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
    Zheng D, Wang R, Ye T, Yu S, Hu H, Shen X, Li Y, Ji H, Sun Y, Chen H.
    Oncotarget; 2016 Jul 05; 7(27):41691-41702. PubMed ID: 27223439
    [Abstract] [Full Text] [Related]

  • 18. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb 05; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 19. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
    Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.
    Clin Cancer Res; 2020 Jan 15; 26(2):439-449. PubMed ID: 31548343
    [Abstract] [Full Text] [Related]

  • 20. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
    Wang SXY, Zhang BM, Wakelee HA, Koontz MZ, Pan M, Diehn M, Kunder CA, Neal JW.
    Anticancer Drugs; 2019 Jun 15; 30(5):537-541. PubMed ID: 30762593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.